Retina

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.

Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy

Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions.

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.

At the ARVO 2025 meeting in Salt Lake City, Utah, Cameron Cummings presented a poster on how retinal microvascular imaging metrics may show sex-specific biomarkers for Parkinson's disease.

New research links genetic risk for schizophrenia to retinal thinning, suggesting early indicators of the disorder may be found in retinal morphology.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in pseudophakic eyes

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.

Novel color created, olo, beyond previous human perception.

A new event called SightLine and a series on adoption, implementation, integration (AII) draw the attention of ophthalmic administrators.

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

Celebrating a half-century of progress with Ophthalmology Times.